Myocardial IschemiaFUSE-HEARTNCT04680689
Assessment of Lesion-Associated Myocardial Ischemia Based on Fusion Coronary CT Imaging
An observational study of Myocardial Ischemia and Myocardial Viability, run by Cardio Med Medical Center at 1 site in Romania.
Trial summary
The aim of the Fused-Heart study is to investigate the impact of a coronary artery stenosis on myocardial function and viability, based on advanced fusion imaging techniques derived from CCTA. Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Myocardial Ischemia, Myocardial Viability, Coronary Stenosis
- What is being tested?
- 128 Multislice CT coronary angiography, 2D Cardiac Transthoracic Echocardiography and Laboratory Blood tests
- How many people
- 100 participants
- Where
- 1 siteRomania
- Study dates
- 30 Jul 2021to 1 Jan 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study will include 100 subjects with coronary lesions depicted by CCTA examination. The study population will consist in: (1) patients with anatomically significant coronary lesions (at least 50% luminal narrowing) on native coronary arteries, or (2) patients surviving an acute myocardial infarction, revascularized or not.
Who may be able to join
- Patients undergoing CCTA examination, with at least one coronary artery lesion producing a luminal narrowing >50%
- Ability to provide informed consent;
- Patients aged at least 18 years;
Who cannot join
- Unwillingness or incapacity to provide informed consent;
- Allergy to contrast media;
- Absolute or relative contraindications to CCTA imaging;
- Irregular or rapid heart rhythm
- Pregnancy or lactation;
- Women with childbearing potential in absence of any contraceptive treatment;
Show all 9Show fewer
- Renal insufficiency (creatinine greater than 1.5 mg/dL) or renal failure requiring dialysis;
- Active malignancy or malignancy within the last 5 year prior to enrollment;
- Conditions associated with an estimated life expectancy of under 2 years;
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Assessment of Lesion-Associated Myocardial Ischemia Based on Fusion Coronary CT Imaging- the FUSE-HEART Study: Protocol for a Non-randomised Clinical Trial
The aim of the Fused-Heart study is to investigate the impact of a coronary artery stenosis on myocardial function and viability, based on advanced fusion imaging techniques derived from CCTA.
Moreover the study will investigate the correlation between morphology and composition of atheromatous plaques located in a coronary artery and myocardial ischemia in the territory irrigated by the same coronary artery.
Read the detailed description
The FUSE-HEART study is a prospective, observational, single-center, cohort study that will be conducted in the Laboratory of Advanced Research in Cardiac Multimodal Imaging of Cardio Med Medical Center Targu Mures, Romania.
The study will include 100 subjects with coronary lesions depicted by CCTA examination. The study population will consist in: (1) patients with anatomically significant coronary lesions (at least 50% luminal narrowing) on native coronary arteries, or (2) patients surviving an acute myocardial infarction, revascularized or not. In all patients, presence of vulnerability features in the atheromatous plaques will be studied and the vulnerability score will be calculated for each plaque, consisting in one point added for each of the following vulnerability markers: positive remodeling, napkin-rink sign, presence of low density plaque or spotty calcium within the plaque. In addition, following 3D fusion of the images of the coronary tree with the images reflecting wall motion, the correspondence between plaque morphology and composition on one hand, and wall motion in the corresponding distribution territory of that coronary artery, will be studied based on fused models.
The study will be conducted over a period of 2 years, in which patients will be examined at baseline, with a projected recruitment period of 1 year and will be followed-up 1 year for MACE.
Study objectives:
Primary: to investigate the impact of a coronary artery stenosis on myocardial function and viability, based on advanced fusion imaging techniques derived from CCTA.
Secondary: to investigate the correlation between morphology and composition of atheromatous plaques located in a coronary artery and myocardial ischemia in the territory irrigated by the same coronary artery.
Study timeline:
- Baseline (day 0)-Obtain and document consent from participant on study consent form.
Verify inclusion/exclusion criteria. Obtain demographic information, medical history, medication history, alcohol and tobacco use history. Record results of physical examinations and 12-lead ECG.Collect blood specimens (complete blood count, biochemistry and inflammatory biomarkers).Imaging procedures: CCTA-Image processing - quantification of coronary stenosis, characterization of vulnerability markers, 3D reconstruction, extension and characterization of wall motion. Deliver fused 3D images
- Visit 1 (month 1)-Record results of physical examinations, 12-lead ECG, blood pressure, and medical history. MACE assessment Visit 2 (month 3) -Telephone visit with target questions, all the answers recorded in study forms Visit 3 (month 6) - Record results of physical examinations, 12-lead ECG, blood pressure, and medical history. MACE assessment
Final study visit (month 12)- Record results of physical examinations, medical history,12-lead ECG, blood pressure, transthoracic 2-D echocardiography. End-point and MACE evaluation.
Study procedures:
- Medical history, clinical examination, laboratory tests (complete blood count, biochemistry, inflammatory biomarkers: hs-CRP, MMP, IL6 and NT-pro-BNP);
- 12-lead ECG
- 2D transthoracic echocardiography
- CCTA
- Computerized postprocessing and fused images
Data collection:
All the information will be collected in a dedicated database including medical history, medication, imaging features provided by cardiac ultrasound, CCTA and fused images resulting from imaging post-processing.
- Being tested
- 128 Multislice CT coronary angiography, 2D Cardiac Transthoracic Echocardiography, Laboratory Blood tests
- Keywords
- Fusion imaging, CCTA, Myocardial viability, Vulnerable coronary plaques
- Medical subject headings
- Myocardial Ischemia, Coronary Stenosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
128 Multislice CT coronary angiographyDiagnostic test
Also called CCTA
128 Multislice CT coronary angiography with the evaluation of coronary stenosis, the plaque vulnerability markers ( necrotic core, low attenuation plaque, spotty calcifications, napkin ring sign, positive remodeling), asses polar maps of the myocardium
2D Cardiac Transthoracic EchocardiographyDiagnostic test
2D Cardiac Transthoracic Echocardiography with the evaluation of the cardiac cavity dimensions
Laboratory Blood testsDiagnostic test
Laboratory tests for evaluations the level of inflammatory biomarkers ( hs-CRP, MMP, IL6 and NT-pro-BNP), complete blood count, biochemestry
| Study group | Role | What they receive |
|---|---|---|
| Fuse-Heart -SG 01 | Study subjects with anatomically significant coronary lesions (at least 50% luminal narrowing) on native coronary arteries. Receives: Diagnostic Test: 128 Multislice CT coronary angiography; Diagnostic Test: 2D Cardiac Transthoracic Echocardiography; Diagnostic Test: Laboratory Blood tests | |
| Fuse-Heart -SG 02 | Study subjects surviving an acute myocardial infarction, revascularized or not. Receives: Diagnostic Test: 128 Multislice CT coronary angiography; Diagnostic Test: 2D Cardiac Transthoracic Echocardiography; Diagnostic Test: Laboratory Blood tests |
What is being measured
The primary outcome is the main question the study is designed to answer.
MACE rate-Major Adverse Cardiovascular Events
The primary outcome of the study is represented by the rate of MACE events related to myocardial ischemia at 1-year post assessment, in correlation with the degree of coronary artery stenosis and myocardial ischemia or viability.
Measured: 12 months
Secondary outcomes (2)
Re-hospitalisation rate,
Secondary outcome refers to rate of re-hospitalization, in correlation with the morphology and composition of atheromatous plaques located in a coronary artery and myocardial ischemia in the territory irrigated by the same coronary artery
Measured: 12 months
Rate of survival
This outcome refers to rate of survival in correlation with the morphology and composition of atheromatous plaques located in a coronary artery and myocardial ischemia in the territory irrigated by the same coronary artery
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Dec 2020
- Study start30 Jul 2021
- Primary completion1 Dec 2022
- Study completion1 Jan 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myocardial IschemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Cardio Med Medical Center
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Targu Mures, Tîrgu Mureș Emergency Clinical County Hospital, Romania
- Responsible party
- Sponsor
- Investigators
- Alexandra Gorea Stanescu, MD, Principal investigator, Cardio Med
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04680689
- Sponsor's protocol ID
- CM0520-FUSEH
- Acronym
- FUSE-HEART
- Status last verified
- Feb 2022
- First submitted
- 14 Dec 2020
- Last updated
- 14 Feb 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All IPD that underlie results in a publication will be available for interested parties
Study at a glance
From the registry record, last updated by the sponsor on 14 Feb 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of Lesion-Associated Myocardial Ischemia Based on Fusion Coronary CT Imaging- the FUSE-HEART Study: Protocol for a Non-randomised Clinical Trial
- ClinicalTrials.gov ID
- NCT04680689
- Acronym / sponsor ID
- FUSE-HEART / CM0520-FUSEH
- Keywords
- Fusion imaging, CCTA, Myocardial viability, Vulnerable coronary plaques
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Cardio Med Medical CenterIndustry (pharma, biotech, devices)
- Collaborators
- George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Targu Mures, Tîrgu Mureș Emergency Clinical County Hospital, Romania
- Study start
- 30 Jul 2021 (actual)
- Primary completion
- 1 Dec 2022 (actual)
- Study completion
- 1 Jan 2023 (actual)
- First posted
- 23 Dec 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the Fused-Heart study is to investigate the impact of a coronary artery stenosis on myocardial function and viability, based on advanced fusion imaging techniques derived from CCTA.
Moreover the study will investigate the correlation between morphology and composition of atheromatous plaques located in a coronary artery and myocardial ischemia in the territory irrigated by the same coronary artery.
Detailed description
The FUSE-HEART study is a prospective, observational, single-center, cohort study that will be conducted in the Laboratory of Advanced Research in Cardiac Multimodal Imaging of Cardio Med Medical Center Targu Mures, Romania.
The study will include 100 subjects with coronary lesions depicted by CCTA examination. The study population will consist in: (1) patients with anatomically significant coronary lesions (at least 50% luminal narrowing) on native coronary arteries, or (2) patients surviving an acute myocardial infarction, revascularized or not. In all patients, presence of vulnerability features in the atheromatous plaques will be studied and the vulnerability score will be calculated for each plaque, consisting in one point added for each of the following vulnerability markers: positive remodeling, napkin-rink sign, presence of low density plaque or spotty calcium within the plaque. In addition, following 3D fusion of the images of the coronary tree with the images reflecting wall motion, the correspondence between plaque morphology and composition on one hand, and wall motion in the corresponding distribution territory of that coronary artery, will be studied based on fused models.
The study will be conducted over a period of 2 years, in which patients will be examined at baseline, with a projected recruitment period of 1 year and will be followed-up 1 year for MACE.
Study objectives:
Primary: to investigate the impact of a coronary artery stenosis on myocardial function and viability, based on advanced fusion imaging techniques derived from CCTA.
Secondary: to investigate the correlation between morphology and composition of atheromatous plaques located in a coronary artery and myocardial ischemia in the territory irrigated by the same coronary artery.
Study timeline:
- Baseline (day 0)-Obtain and document consent from participant on study consent form.
Verify inclusion/exclusion criteria. Obtain demographic information, medical history, medication history, alcohol and tobacco use history. Record results of physical examinations and 12-lead ECG.Collect blood specimens (complete blood count, biochemistry and inflammatory biomarkers).Imaging procedures: CCTA-Image processing - quantification of coronary stenosis, characterization of vulnerability markers, 3D reconstruction, extension and characterization of wall motion. Deliver fused 3D images
- Visit 1 (month 1)-Record results of physical examinations, 12-lead ECG, blood pressure, and medical history. MACE assessment Visit 2 (month 3) -Telephone visit with target questions, all the answers recorded in study forms Visit 3 (month 6) - Record results of physical examinations, 12-lead ECG, blood pressure, and medical history. MACE assessment
Final study visit (month 12)- Record results of physical examinations, medical history,12-lead ECG, blood pressure, transthoracic 2-D echocardiography. End-point and MACE evaluation.
Study procedures:
- Medical history, clinical examination, laboratory tests (complete blood count, biochemistry, inflammatory biomarkers: hs-CRP, MMP, IL6 and NT-pro-BNP);
- 12-lead ECG
- 2D transthoracic echocardiography
- CCTA
- Computerized postprocessing and fused images
Data collection:
All the information will be collected in a dedicated database including medical history, medication, imaging features provided by cardiac ultrasound, CCTA and fused images resulting from imaging post-processing.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Fuse-Heart -SG 01 | – | Diagnostic Test: 128 Multislice CT coronary angiography, Diagnostic Test: 2D Cardiac Transthoracic Echocardiography, Diagnostic Test: Laboratory Blood testsStudy subjects with anatomically significant coronary lesions (at least 50% luminal narrowing) on native coronary arteries. |
| Fuse-Heart -SG 02 | – | Diagnostic Test: 128 Multislice CT coronary angiography, Diagnostic Test: 2D Cardiac Transthoracic Echocardiography, Diagnostic Test: Laboratory Blood testsStudy subjects surviving an acute myocardial infarction, revascularized or not. |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study will include 100 subjects with coronary lesions depicted by CCTA examination. The study population will consist in: (1) patients with anatomically significant coronary lesions (at least 50% luminal narrowing) on native coronary arteries, or (2) patients surviving an acute myocardial infarction, revascularized or not.
Key inclusion criteria (3 listed)
- Patients undergoing CCTA examination, with at least one coronary artery lesion producing a luminal narrowing >50%
- Ability to provide informed consent;
- Patients aged at least 18 years;
Key exclusion criteria (9 listed)
- Unwillingness or incapacity to provide informed consent;
- Allergy to contrast media;
- Absolute or relative contraindications to CCTA imaging;
- Irregular or rapid heart rhythm
- Pregnancy or lactation;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 128 Multislice CT coronary angiographyAlso: CCTA128 Multislice CT coronary angiography with the evaluation of coronary stenosis, the plaque vulnerability markers ( necrotic core, low attenuation plaque, spotty calcifications, napkin ring sign, positive remodeling), asses polar maps of the myocardium | Diagnostic test | Fuse-Heart -SG 01, Fuse-Heart -SG 02 |
| 2D Cardiac Transthoracic Echocardiography2D Cardiac Transthoracic Echocardiography with the evaluation of the cardiac cavity dimensions | Diagnostic test | Fuse-Heart -SG 01, Fuse-Heart -SG 02 |
| Laboratory Blood testsLaboratory tests for evaluations the level of inflammatory biomarkers ( hs-CRP, MMP, IL6 and NT-pro-BNP), complete blood count, biochemestry | Diagnostic test | Fuse-Heart -SG 01, Fuse-Heart -SG 02 |
Primary outcome
MACE rate-Major Adverse Cardiovascular Events
Time frame: 12 months
The primary outcome of the study is represented by the rate of MACE events related to myocardial ischemia at 1-year post assessment, in correlation with the degree of coronary artery stenosis and myocardial ischemia or viability.
2 secondary outcomes
Re-hospitalisation rate,
Time frame: 12 months
Rate of survival
Time frame: 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Feb 2023.
- Individual participant dataSharing planned: Yes. All IPD that underlie results in a publication will be available for interested parties
Related trials for Myocardial Ischemia
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
RecruitingEarly Phase 1
Thiamine Intervention and Coronary Artery Bypass Grafting
Coronary Heart Disease, Coronary Artery Bypass Grafting
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alexandra Gorea Stanescu, MD principal investigator
Cardio Med
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Myocardial Ischemia and Myocardial Viability, run by Cardio Med Medical Center at 1 site in Romania.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Romania. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MACE rate-Major Adverse Cardiovascular Events (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Feb 2023.